TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $125

TD Cowen analyst Joseph Thome has maintained a 'Buy' rating on Mirum Pharmaceuticals (NASDAQ: MIRM) and raised the price target from $117 to $125. This adjustment reflects the analyst's positive outlook on the company's performance.